YM-53601 inhibits squalene synthetase activity in rat hepatic microsomes and human HepG2 cells. YM-53601 can also inhibit cholesterol biosynthesis (ED50 = 32 mg/kg), causing a reduction in both cholesterol and triglyceride levels in plasma. The lipid-lowering properties of compounds such as YM-53601 make them interesting research opportunities for alternatives to combination HMG-CoA reductase inhibitor/fibrate therapy.
1. Ugawa, T., et al., 2000. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. British journal of pharmacology. 131(1): 63-70. PMID: 10960070
2. Ishihara, Tsukasa., et al., 2003. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorganic & medicinal chemistry. 11(17): 3735-45. PMID: 12901918
See how others have used YM-53601 (CAS 182959-33-7). Click on the entry to view the PubMed entry .
PMID: # 26698156 Stäubert, C. et al. 2016. Med. Oncol. 33: 6.
PMID: # 26908642 Alarcon, VB. et al. 2016. Mol. Hum. Reprod. 22: 350-63.
PMID: # 18593925 Montero, J. et al. 2008. Cancer Res. 68: 5246-5256.